<DOC>
	<DOCNO>NCT01176409</DOCNO>
	<brief_summary>The purpose study compare level immune inflammatory marker among HIV-1 , HSV-2 co-infected adult achieve plasma HIV RNA suppression &lt; 50 copies/mL , randomize valacyclovir placebo , twelve-week intervention period .</brief_summary>
	<brief_title>Can Valacyclovir Attenuate Inflammation Antiretroviral-Treated HIV-Infected Individuals With Herpes Simplex Virus Type 2 ?</brief_title>
	<detailed_description>Highly active antiretroviral therapy ( HAART ) dramatically reduce HIV-1 infection ( herein refer 'HIV ' ) relate morbidity mortality , transform invariably fatal disease manageable , chronic condition . Yet even HAART-treated HIV infection characterize chronic systemic inflammation immune activation . This systemic inflammatory response compose multiple component , quantify measure marker immune activation , inflammatory cytokine , acute phase reactant , endothelial activation marker , marker microbial translocation . This inflammation clinically relevant , may contribute directly HIV disease progression non-AIDS related morbidity mortality HIV-infected patient . Because inflammation persists even context suppressive HAART , albeit modestly decrease level , adjunctive therapeutic strategy attenuate persistent inflammatory response therefore need . Herpes simplex virus type 2 common , clinically important co-infection see individual live HIV infection , may contribute ongoing inflammation . This pilot trial investigate whether short-term valacyclovir HSV-2 suppression decrease systemic inflammation HAART-treated , HIV-1 , HSV-2 co-infected individual .</detailed_description>
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Herpes Simplex</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>adult ( age 18 year old ) document HIV1 infection ( determine EIA Western blot ) document HSV2 seropositivity ( determine ELISA screen ) use chronic antiHSV therapy past 6 month , anticipate require chronic antiHSV therapy study sustain plasma HIV RNA &lt; 50 copies/mL HAART least 12 month active opportunistic infection least 12 month hepatitis C coinfection hepatitis B coinfection pregnancy actively plan become pregnant receive chemotherapy , chronic steroid therapy immunomodulatory medication ( e.g . interferon , azathioprine , methotrexate , TNFalpha antagonists , etc . ) Estimated creatinine clearance &lt; 30 mL/min Other medical condition likely cause death within 24 month Enrolled interventional clinical trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>